Eli Lilly (LLY) announced that it had achieved positive results from a phase 1/2 study using the drug selpercatinib to treat RET fusion-positive non-small cell lung cancer ((NSCLC)). This is good clinical data because it adds RET to the list of genetically mutated alterations that can be targeted by using specific types of therapies. Selpercatinib was acquired by Eli Lilly when it offered to pay $8 billion to buy Loxo Oncology back in January of 2019. With Loxo's pipeline, Eli Lilly should continue to see success in treating specific types of cancers that